(BMY) Bristol-Myers Squibb - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1101221083
BMY: Medicines, Treatments, Drugs, Vaccines, Therapy, Pills
Bristol-Myers Squibb Company (BMY) stands as a global leader in the biopharmaceutical industry, renowned for its innovative approach to treating serious diseases. With a rich history dating back to 1887, BMY has consistently demonstrated a commitment to R&D, investing heavily in cutting-edge therapies that address significant unmet medical needs.
The companys diverse portfolio is a testament to its strategic prowess, featuring blockbuster drugs like Eliquis, which dominates the anticoagulant market, and Opdivo, a flagship immunotherapy that has revolutionized cancer treatment. Their pipeline is robust, with recent FDA approvals for therapies targeting multiple myeloma and melanoma, underscoring their dedication to innovation and patient care.
Financially, BMY presents a compelling case for investors. With a market cap exceeding $109 billion, the company boasts a strong balance sheet and a dividend yield that attracts income-focused investors. Their forward P/E ratio of 8.06 suggests a balanced valuation, considering their growth prospects and established product portfolio.
BMYs strategic initiatives, including partnerships and acquisitions, have fortified their position in the pharmaceutical market. Their focus on emerging therapies, such as CAR-T cell treatment Breyanzi, highlights their commitment to staying at the forefront of medical innovation. This forward-looking approach, coupled with a solid financial foundation, positions Bristol-Myers Squibb as a resilient player in the ever-evolving biopharma landscape.
Additional Sources for BMY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BMY Stock Overview
| Market Cap in USD | 123,971m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1972-01-01 |
BMY Stock Ratings
| Growth 5y | 29.4% |
| Fundamental | -18.3% |
| Dividend | 63.1% |
| Rel. Strength Industry | 20.5 |
| Analysts | 3.38/5 |
| Fair Price Momentum | 59.31 USD |
| Fair Price DCF | 158.75 USD |
BMY Dividends
| Dividend Yield 12m | 4.40% |
| Yield on Cost 5y | 5.67% |
| Annual Growth 5y | 0.94% |
| Payout Consistency | 92.4% |
BMY Growth Ratios
| Growth Correlation 3m | 48.9% |
| Growth Correlation 12m | 80.2% |
| Growth Correlation 5y | -4.1% |
| CAGR 5y | 7.15% |
| CAGR/Max DD 5y | 0.15 |
| Sharpe Ratio 12m | 1.11 |
| Alpha | 16.66 |
| Beta | -0.16 |
| Volatility | 27.87% |
| Current Volume | 8990.4k |
| Average Volume 20d | 11012k |
As of March 14, 2025, the stock is trading at USD 60.28 with a total of 8,990,365 shares traded.
Over the past week, the price has changed by +0.17%, over one month by +7.70%, over three months by +9.26% and over the past year by +20.21%.
Neither. Based on ValueRay Fundamental Analyses, Bristol-Myers Squibb is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.32 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BMY as of March 2025 is 59.31. This means that BMY is currently overvalued and has a potential downside of -1.61%.
Bristol-Myers Squibb has received a consensus analysts rating of 3.38. Therefor, it is recommend to hold BMY.
- Strong Buy: 4
- Buy: 4
- Hold: 17
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, BMY Bristol-Myers Squibb will be worth about 64.1 in March 2026. The stock is currently trading at 60.28. This means that the stock has a potential upside of +6.25%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 61.2 | 1.6% |
| Analysts Target Price | 61 | 1.2% |
| ValueRay Target Price | 64.1 | 6.3% |